The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

Provided are peptides, modified peptides, fragments thereof, conjugates thereof, and polymers thereof that have antibacterial activity against bacterial that include but are not limited to multidrug-resistant bacteria. In some embodiments, the presently disclosed subject matter relates to peptides that include the amino acid sequences RTVRCTCI (SEQ ID NO: 2), LSRTVRCTCISI (SEQ ID NO: 3) or VPLSRTVRCTCISI (SEQ ID NO: 4), PESK AIKNLLK AV SKERSKRSP (SEQ ID NO: 11), or KNLLK AV SKERSKRSP (SEQ ID NO: 12), modified peptides thereof, fragments thereof, and conjugates thereof, and any combination thereof. The peptides, modified peptides, fragments thereof, and conjugates thereof can be polymer-functionalized, encapsulated in a particle, embedded in and/or on a solid support, optionally wherein the peptide is formulated for release from the solid support, impregnated in a dressing, optionally wherein the peptide is formulated for release from the dressing, and/or is formulated for use in a nebulizer, for topical administration, and/or for systemic administration. Also provided are medical devices having a support layer with an antibacterial agent embedded therein or associated therewith, methods for inhibiting the growth of and/or killing bacteria, for recruiting immune cells to site of infection, for treating or preventing community and/or nosocomial infections, for inducing a subjects immune system against a pathogen, for treating bacterial infections present in wounds, for treating pulmonary infections, for treating or preventing systemic bacterial infections, and for combination therapies with conventional antibiotics.

Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein.

An adenovirus comprising a sequence of formula (I) 5′ITR-B.sub.1-B.sub.A-B.sub.2-B.sub.X-B.sub.B-B.sub.Y-B.sub.3-3′ITR wherein B.sub.Y comprises a transgene cassette containing four transgenes, said genes encoding a FAP-Bispecific T cell activator, CXL10, CXL9, and IFN. The disclosure also extends to a pharmaceutical composition comprising the virus, and use of the virus or formulation in treatment.

The present disclosure provides methods of using the CXCL12-α2 locked dimer polypeptide to mobilize cancer cells and hematopoietic stem cells into the bloodstream of a subject.

Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.

Described are mutant Platelet Factor 4 (PF4) proteins that exhibit different binding affinities to vaccine induced immune thrombotic thrombocytopenia (VITT) antibodies or non-heparin-induced thrombocytopenia (non-HIT) antibodies relative to heparin-induced thrombocytopenia (HIT) antibodies. Also provided herein are methods for differentiating between VITT, HIT, and/or non-HIT in subjects suspected of having VITT, HIT, or non-HIT.

The present disclosure provides compositions and methods for treating an infection by EV-D68. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by EV-D68.

The present invention relates to methods for treatment of capillary leak syndrome and acute respiratory distress syndrome using CXCL12 peptides, specifically a constitutively monomeric CXCL12 peptide or a CXCL12 locked dimer polypeptide.

The disclosure relates to oncolytic virus derived replicons and capsidation of the same. The disclosure also relates to the incorporation of one or more transgenes encoding payload molecules into the replicon. The disclosure further relates to the encapsulation of the replicon and/or recombinant RNA molecules encoding oncolytic viruses into particles and the use of the replicon and/or particles for the treatment and prevention of cancer.